Equity Overview
Price & Market Data
Price: $26.02
Daily Change: -$0.14 / 0.54%
Daily Range: $25.29 - $26.36
Market Cap: $1,544,217,216
Daily Volume: 576,044
Performance Metrics
1 Week: -4.20%
1 Month: -4.36%
3 Months: 15.18%
6 Months: 32.35%
1 Year: 21.19%
YTD: 68.96%
Company Details
Employees: 62
Sector: Health technology
Industry: Biotechnology
Country:
Details
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.